> News
 > MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
News
26/04/2023

MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease

Lyon, France, April 24, 2023, 7:30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported that the U.S. Food and Drug Administration (FDA or the “Agency”) has lifted the clinical hold[…]

Access the press release

 

 

 

 

 

 

 

 

 

 

Our news

News
11/01/2023
Organic S. boulardii: A Probiotic Breakthrough by Lallemand
> READ
News
09/11/2023
Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members
> READ
Events
19/01/2023
Microbiota & Health Day 2023
> READ
> See all news